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Background
To our knowledge, the antiviral activity of pegylated
interferon alfa plus HAART has not been studied in
patients with human immunodeficiency virus type 1
(HIV-1) coinfected with chronic hepatitis B virus (HBV).
Objective
To evaluate the effectiveness of pegylated interferon alfa
plus HAART in HIV/HBV treatment-naïve coinfected
patients.
Methods
We performed a prospective cohort study in HIV/HBV
treatment-naïve coinfected patients taking care at “La
Raza” National Medical Center, Mexico City. Patients
were treated with Efavirenz or Lopinavir-ritonavir, each
with tenofovir/emtricitabine plus pegylated interferon
alfa-2b (1.5 µg/kg/week) or pegylated interferon alfa-2a
(180 µg/week) during 48 weeks. HBV genetic analysis
was obtained. The study had a primary measure of
effectiveness assessed at 24 and 48 weeks of treatment:
suppression of HIV RNA to levels below 50 IU/ml. Sec-
ondary endpoints were increased in CD4+ cells count,
HBV DNA to levels below 60 IU/ml, HBeAg serocon-
version (defined by the loss of HBeAg and the presence
of anti-HBe antibody) and HBsAg seroconversion
( d e f i n e db yt h el o s so fH B s A ga n dt h ep r e s e n c eo fa n t i -
HBs antibody). Cumulative incidence with 95% confi-
dence interval (95%CI) were calculated.
Results
We enrolled 18 subjects, 1 patient discontinued treat-
ment because adverse events related to PEG-IFN. The
mean (± SD) age was 30.3 ± 6.9 years old, all patients
were men. The median (interquartile range) basal CD4+
cells count was 112 (61 to 300), RNA HIV 163,000
copies/ml (9,545 to 636,500 copies/ml), DNA HBV
20,200,000 IU/ml (627,500 to 480,500,000 IU/ml). All
patients had positive HBeAg and were negative to HDV
serology. HBV genotype distribution was H 9 (52%), G 6
(35%), A 1 (6%) and F 1 (6%). Primary endpoint (RNA
HIV < 50 copies/ml) was present in 100% of our patient
at 24 and 48 weeks; the median increased in CD4+ cells
count was 231 cells/ml at 24 weeks and 322 cells/ml at
48 weeks; cumulative incidence of secondary endpoints
were: DNA HBV < 60 UI/ml was present in 8 patients
[47% CI95% 26-69%)] at 24 weeks and 17 patients (100
%) at 48 weeks; HBeAg seroconversion was in 8 patients
[47% CI95% 26-69%)] at 24 weeks and 16 patients [94%
CI95% 73-98%)] at 48 weeks, HBsAg seroconversion was
in 0 patients (0%) at 24 weeks and 6 patients [35%
CI95% 17-58%)] at 48 weeks.
Conclusions
Pegylated interferon alfa plus HAART were well toler-
ated and exhibited high viral effectiveness in HIV/HBV
treatment-naïve coinfected patients.
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